<p>Alfresa Holdings Corporation has provided its earnings forecast for the fiscal year ending March 31, 2026, noting that the “Other Businesses” segment was newly established in fiscal 2025. For the third quarter of the fiscal year ending March 2026, Alfresa reported a year-on-year increase in net sales and operating profit, driven by cost control and revenue growth. The ethical pharmaceutical segment showed a market share increase of 0.5 percentage points to 24.8%, with net sales rising 4.9% compared to the previous year. Despite challenges such as NHI drug price revisions and rising logistics costs, Alfresa achieved a 4.5% increase in consolidated net sales and a 1.5% rise in gross profit for the period. Notably, the financial forecast for the Self-Medication Products Wholesaling Business segment was revised upward on February 10, 2026, reflecting strong progress through the third quarter. However, the pharmaceutical manufacturing segment faced a decline in net sales and operating profit due to lower pharmaceutical sales after NHI price revisions and the introduction of new fees for long-listed drugs. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alfresa Holdings Corporation published the original content used to generate this news brief on February 10, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here</p>

Alfresa Holdings Raises Full-Year Forecast for Self-Medication Products Segment